This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
by Zacks Equity Research
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength
by Zacks Equity Research
Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 85.4% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -9.09% and 3.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
by Zacks Equity Research
Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 34.7% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 3.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Can VAALCO (EGY) Deliver Strong Q4 Earnings Performance?
by Zacks Equity Research
While lower commodity prices are likely to have hurt VAALCO Energy's (EGY) Q4 bottom line, an impressive production profile might somewhat aid results.
Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
by Zacks Equity Research
Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice
by Zacks Equity Research
Does Ocular Therapeutix (OCUL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 64.6% in Ocular Therapeutix (OCUL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 134.8% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick
by Zacks Equity Research
Ocular Therapeutix (OCUL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 14.71% and 3.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Stevanato Group (STVN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 7.14% and 0.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?
by Zacks Equity Research
Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chinook (KDNY) delivered earnings and revenue surprises of -13.92% and 28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?